

EINNEWS

**PRESS RELEASE
NEWSWIRE SERVICE
EXCLUSIVE**

Kibow Biotech Founder is Keynote Speaker at the International Drug Discovery Science and Technology (IDDST) Congress in Beijing, China

October 15, 2008 **/EIN News/** -- PHILADELPHIA, PA., October 14, 2008 - Kibow Biotech, Inc. has just announced that Dr. Natarajan Ranganathan, VP (R&D) and interim CEO, has been invited to be a Keynote Speaker at the prominent International Drug Discovery Science and Technology Congress in China. The meeting will take place October 18-22, at the Loong Palace Hotel in Beijing.

The title of Dr. Natarajan Ranganathan's presentation is, "Discovering Enteric Dialysis - The Gut Based Uremia Therapy for Chronic Kidney Failure Applications/."

Dr. Natarajan Ranganathan, VP (R&D) and interim CEO of the Newtown Square, Pennsylvania, based company, said, "Kibow Biotech is honored to have been invited to be a keynote speaker in the area of "Microbiology, Virology and Drug Discovery." Dr. Ranganathan went on to say, "...we are especially pleased to be sharing the stage with many prominent speakers, including Nobel Prize Laureates and Bio-Pharma Industry leaders."

The Congress expects to attract over 1,500 attendees who will exchange ideas, build new networks and foster friendship. Over 500 brilliant scientific, technology and business presentations will be given. Additionally, there will be 100 scientific posters presenting exciting research achievements. Business plans and investment opportunities will also be discussed.

Kibow Biotech will also be exhibiting the company's first generation product called Kibow Biotics(R), an orally consumable, enteric coated gel cap product formulation that is composed of food grade microbes ("Probiotics"). A proprietary formulation, Kibow Biotics(R) metabolize uremic toxins diffusing from the blood into the bowel.. The process is called Enteric Dialysis. It is targeted to help augment or maintain kidney function both for Chronic Kidney Failure (CKF) patients (pre-dialysis) and End Stage Renal Disease (ESRD) patients.

SOURCE: Kibow Biotech, Inc.

For additional information, contact:

Dr. Natarajan Ranganathan
CEO and VP Research and Development
Kibow Biotech, Inc.
4629 West Chester Pike
Newtown Square, PA 19073 USA
Tel: (610) 353 5130
Fax: (610) 353 5110
Email address: rangan@kibowbiotech.com

Web site: <http://www.kibow.com>

About Kibow Biotech

Kibow Biotech Inc. is an eleven-year-old, developing-stage biotechnology company having its operations in Newtown Square, PA, USA. The company is dedicated to finding a simple, convenient and cost-effective worldwide solution for patients suffering from kidney failure.

About Kibow Biotics

Kibow Biotics(R) is an orally administered patented formulation of specially developed strains of naturally occurring bacteria or microbes which metabolize targeted uremic toxins in the gut and incorporate them as nutrients for growth. Clinical evidence shows that it may reduce bloodstream concentrations of urea, uric acid, creatinine, indoles and phenols, nitrosamines and related uremic metabolites. Kibow also believes that Kibow Biotics(R) promote maintenance of normal

healthy gut flora.

For more information, visit <http://www.kibow.com>

Forward- looking statements

This press release contains forward- looking statements that reflect management's current views of future events, including the status of development of the dietary supplement formulation, Kibow Biotics(R), for kidney failure applications, and the possible benefits of Kibow Biotics in slowing the progression of chronic kidney failure or helping patients feel better. Kibow is not a pharmaceutical company. Kibow products are not drugs and may not be considered as a treatment or a therapy. The dietary supplement formulation of Kibow Biotics will not cure, prevent or mitigate any disease. Actual results may differ significantly from the above forward-looking statements due to a number of factors including but not limited to the possibility that Kibow Biotics(R) may not prove to be safe or show evidence of clinical activity in the current limited human trials or that data from patients enrolled in the study may not be useful or conclusive or sufficient to guide future development of Kibow Biotics(R). Other factors that could cause or contribute to differences in actual results include, but are not limited to, whether or not the Company or any of its collaborators will be able to develop dietary supplements using the technologies of the Company, risks associated with completing clinical trials of product candidates, the possibility that clinical testing may reveal to be undesirable and unintended side effects or other characteristics that may prevent or limit the commercial use of proposed products; whether the cash resources of the Company will be sufficient to fund operations as planned; reliance on key employees, especially senior management; the uncertainty of the Company's future access to capital; the risk that the Company may not secure or maintain relationships with collaborators, and the Company's dependence on intellectual property. The Company expressly disclaims any intent or obligation to update these forward-looking statements except as required by law.